AMWL

American Well Corp (AMWL) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. American Well Corporation is a leading enterprise software company enabling digital delivery of care. The company operates as a single reportable segment, providing the Amwell Platform for hybrid care delivery to health systems, health plans, and government entities. The company is currently executing strategic transformation actions to align its cost structure with its revenue profile.

Key Financial Metrics

Note: Revenue decreased due to timing of recognition with strategic customers and declines in professional services, partially offset by higher visit revenue. Operating cash flow turned positive YTD 2026 compared to a significant outflow in YTD 2025.

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased 27% in Q2 and 22% YTD compared to the prior year. This was driven by a $14.8 million decrease in subscription revenue (timing of recognition) and a $5.8 million decrease in "Other" revenue (professional services and marketing).
• Expense Reduction: Total operating expenses decreased 33% in Q2 and 29% YTD. Significant reductions were seen in Sales & Marketing (down 53% Q2) and R&D (down 43% Q2) due to headcount reductions (24-52% depending on department) and reduced stock-based compensation.
• Loss Improvement: Net loss attributable to American Well Corporation improved by 50% in Q2 and 46% YTD, primarily due to the aggressive cost-cutting measures.
• Divestiture Gain: The company recognized a $7.0 million gain on divestiture in the first half of 2026 related to the contingent consideration from the sale of the APC business (telepsychiatry services).
• Impairment Charge: A $3.4 million impairment charge was recorded in Q2 2026 related to the abandonment of the corporate headquarters right-of-use asset.

Outlook, Risks, and Management Commentary

• Strategic Transformation: Management continues to execute strategic transformation actions, including headcount reductions and lease abandonments, to improve profitability. Remaining costs for these actions are approximately $3.6 million.
• Visit Volume: Total visits declined to 1.9 million in the first half of 2026 (down from 2.5 million in the prior year) due to customer churn, lower urgent care/behavioral visits, and summer seasonality.
• Liquidity: The company holds $195.9 million in cash and cash equivalents with no debt. Management believes this is sufficient to meet working capital needs for at least the next 12 months.
• Risks: Key risks include the continuation of the Defense Health Agency relationship beyond Q3 2026, customer concentration (one client represented 65% of receivables), and the potential inability to achieve profitability.
• Guidance: The filing does not provide specific numerical guidance for future periods but emphasizes the focus on the Amwell Platform and path to profitability.

Investor Verification Checklist

• Customer Concentration: Verify the status of the single client representing 65% of accounts receivable and the top two clients representing 57% of Q2 revenue.
• Subscription Revenue Timing: Investigate the specific reasons for the $14.8 million decrease in subscription revenue attributed to "timing of revenue recognition" with strategic customers.
• Visit Volume Trends: Assess the sustainability of the visit volume decline and the impact of customer churn on future recurring revenue.
• Strategic Transformation Costs: Monitor the $3.6 million in remaining severance and transformation costs and any potential for additional future charges.
• Defense Health Agency Contract: Confirm the renewal status and financial terms of the government contract expected to conclude in Q3 2026.